The relationship between HBV antigens deposition in kidneys and renal prognosis in IgA nephropathy patients infected with HBV Authors: Yun Guo, Shangmei Li, Jiali Wei, Mianna Luo, Huafeng Liu Published: 2024 ABSTRACT AbstractBackgroundHepatitis B virus (HBV) is a risk factor for the progression of immunoglobulin A (IgA) nephropathy. The effect of HBV antigens deposition in kidneys and treatment influencing HBV deposition requires further investigation.MethodsWe analyzed 198 patients with IgAN, including 99 patients with HBV infection and 99 propensity score-matched patients without HBV infection. The primary outcome was a composite of 30% decrease in eGFR from the baseline, kidney failure and all-cause mortality. A Cox proportional hazard model was used to assess the impact of both HBV positive in the serum and HBV antigens deposition in the kidneys on renal outcomes.ResultsAmong 198 individuals, 27 primary composite outcome events were observed, of which 20 (20%) in the HBV positive group and seven (7%) were in the HBV-negative group. The former had a 2.72-fold increased risk of primary outcome events (adjusted hazard ratio: 2.22; 95% confidence interval: 0.89–5.53). HBV antigens deposition in kidneys increased the risk significantly after adjusting for confounders at the latest follow-up (adjusted hazard ratio: 7.49; 95% confidence interval: 1.00–56.04). Antiviral treatment did not influence the deposition of HBV antigens.ConclusionsHBV antigen deposition in the kidneys, compared with no deposition in the kidneys, was associated with a 7.49-fold increased risk of renal prognosis in patients with IgA nephropathy. Introduction Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease characterized by the predominant deposition of IgA in the mesangial area of renal glomeruli [1]. The exact pathogenesis of IgAN remains incompletely elucidated but emerging evidence shows that dysregulated immune cells play a pivotal role in IgAN pathogenesis [2–6]. Approximately 40% of patients with IgAN progress to kidney failure over a period of 10–20 years [7]. Hepatitis B virus (HBV) belongs to the family of Hepadnaviridae and has various proteins, including HBsAg, HBeAg, HBcAg, viral polymerase, and HBx protein [8]. Upon entering the human body, immune-competent individuals can achieve HBsAg clearance mediated by immune cells such as dendritic cells and T cells. The covalently closed circular DNA (cccDNA) is difficult to eradicate, providing a reservoir for potential HBV reactivation due to the HBV X protein regulates viral cccDNA transcription. Additionally, the HBsAg in individuals with impaired immune function may not be completely eliminated [9–11]. HBV infection is globally prevalent. There were approximately 296 million individuals with chronic HBV infection worldwide [12]. The current HBV prevalence of the general population is around 7% in China [13]. Previous study shows that around 20% of IgAN patients are infected with HBV and indicated that HBV is an independent risk factor for the progression of IgAN. Paradoxically, patients receiving antiviral treatment exhibited poorer prognosis compared to those without such treatment [14]. Conversely, another study indicates that IgAN patients with HBV infection do not experience worsened outcomes with antiviral therapy [15]. These findings highlight the intricate relationship between HBV infection and IgAN progression. Additionally, HBV affects not only the liver but also potentially impacts the kidneys [16,17]. Currently, a single study has reported HBV antigens deposition in kidney, which does not appear to affect renal prognosis [15]. Notably, medication used for HBV treatment may influence the result. Thus, comprehensive investigation is essential to elucidate the association between HBV antigens deposition in kidneys and renal prognosis. Subsequently, understanding the factors influencing the deposition of HBV antigens in kidneys is critical. To address these important questions, we conducted the following study, aiming to provide deeper insights into the complex relationship between HBV infection, kidney involvement, and renal outcomes in IgA nephropathy. Methods Study cohort A total of 748 patients with biopsy-confirmed IgAN were enrolled in this study at the Department of Nephrology, Affiliated Hospital of Guangdong Medical University, between January 2013 to June 2023. After excluding patients younger than 14 years old, those with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at the time of biopsy, lacking HBV data, and those complicated with other glomerulonephritis, a total of 113 patients were excluded. The flow chart of sample selection is depicted in Figure 1. IgAN patients who tested negative for serum hepatitis B virus were categorized into the HBV-negative (HBV-) group (n = 536), while those who tested positive were categorized into the HBV-positive (HBV+) group (n = 99). This study was approved by the ethics committee of Affiliated Hospital of Guangdong Medical University. Informed consent was obtained from all the patients. Flow chart of the study. Clinical and pathological variables The clinical characteristics at baseline were extracted at the time of the renal biopsy. Blood pressure was defined as the nearest available value recorded within 30 days of the biopsy. The eGFR value was calculated utilizing the creatinine equation established by the Chronic Kidney Disease Epidemiology Collaboration [18]. The most recent clinical characteristics were documented during the latest follow-up visit. Pathological data were documented using the Oxford MEST (mesangial hypercellularity, endocapillary cellularity, segmental sclerosis, and interstitial fibrosis/tubular atrophy) classification of IgAN based on renal biopsy findings [19]. HBV antigens (HBsAg and HBcAg) deposition in renal tissue was identified via frozen section immunofluorescence analysis. The indirect immunofluorescence method was employed for identifying hepatitis B virus markers. Briefly, the glass slide was removed from refrigeration and allowed to air dry slightly (ensuring it did not over-dry). Primary antibodies targeting HBsAg (GT222429) and HBcAg (GB058629) were applied, followed by incubation in a humidified chamber at room temperature for 40 min. The slide was then rinsed in physiological saline for 3 min, and excess saline was gently removed. FITC-conjugated secondary antibodies were subsequently added, and the slide was incubated again in a humidified chamber at room temperature for an additional 40 min. The reaction was terminated by a final rinse with physiological saline. Fluorescence microscopy was used to evaluate the slides. Outcomes The primary outcome encompassed a composite of events, including a 30% decrease in eGFR from the baseline, the onset of kidney failure (including initiation of maintenance dialysis, kidney transplantation, and eGFR < 15 mL/min/1.73 m2), and all-cause mortality. Statistical analysis The characteristics are presented as mean (SD) or median (interquartile range) for continuous variables and as number (percentage) for categorical variables. The independent samples t-test was employed for comparisons of continuous variables with normal distributions, while the Mann–Whitney U-test was used for those with non-normal distributions. For categorical variables, comparisons were conducted using Pearson’s chi-square test and Fisher’s exact test. Statistical significance was determined using a two-tailed p-value of less than 0.05. Propensity score-matching method (PSM) was used to obtain a 1:1 matched cohort of patients who infected with HBV versus those without HBV. During this process, data from all eligible patients were utilized, consisting of age, sex, blood pressure, urine protein creatinine ratio, eGFR, serum albumin as predictors. The R package MatchIt (version 4.2.3) was applied to perform 1:1 matched pairs of patients of the two groups, with nearest neighbor matching on the propensity scores with a caliper of 0.03. The R packages Survival and Survminer were used to assess the curves of cumulative incidence of the composite outcomes stratified by the HBV infection status in the matched cohort. We evaluated the impact of HBV on primary composite outcomes and its components in the matched cohort using Cox proportion hazard model, with or without adjustment for confounders, including age, sex, blood pressure, urine protein creatinine ratio, eGFR, serum albumin. Unadjusted and adjusted hazard ratios, along with their corresponding 95% confidence intervals, were estimated from the models. We additionally conducted subgroup analyses stratified by baseline characteristics, including age (age < 35 years, age ≥ 35 years), sex, proteinuria (< 1.5 g/24 h, ≥ 1.5 g/24 h), and eGFR (<60 mL/min/1.73m2, ≥ 60 mL/min/1.73m2). A two-sided P value of 0.05 was considered statistically significant. Results Study population characteristics During the study period, a total of 748 patients diagnosed with IgAN were identified. Following the application of exclusion criteria, 635 patients were eligible for analysis, comprising 536 noninfected with HBV and 99 infected with HBV patients. The mean (SD) age was 35 (12) years, the mean (SD) proteinuria level was 1.53 (1.95) g/24h, and the mean (SD) eGFR was 88.76 (29.03) ml/min/1.73 m2. Among the study cohort, we selected a propensity-matched cohort encompassing 99 patients with HBV infection and 99 propensity-matched patients without HBV infection (Figure 1). The baseline characteristics of the cohort categorized by the HBV infection status before and after matching are presented in Table 1. In the propensity score-matched cohort, two groups were well balanced in clinical variables. Table 1.Baseline characteristics of patients with immunoglobulin a nephropathy stratified by HBV infection before and after propensity score matching.VariablesBefore PSM After PSM HBV-(n = 536)HBV+(n = 99)P valueHBV-(n = 99)HBV+(n = 99)P valueAge, years35.11 (12.37)35.93 (10.05)0.5335.95 (12.36)35.93 (10.05)0.99Male250 (46.64%)50 (50.5%)0.4847 (47.5%)50 (50.5%)0.67SBP, mmHg128.8 (20.17)127.6 (19.38)0.60126.0 (17.01)127.6 (19.38)0.53DBP, mmHg78.45 (12.50)78.56 (11.70)0.9476.88 (13.01)78.56 (11.70)0.34Proteinuria, g/24h1.56 (2.04)1.33 (1.37)0.311.29 (1.54)1.33 (1.37)0.83eGFR, ml/min/1.73 m289.38 (29.01)86.66 (28.63)0.3883.99 (29.32)86.66 (28.63)0.52Serum albumin, g/l39.64 (7.99)39.56 (8.38)0.9439.89 (6.92)39.56 (8.38)0.77CKD stages 0.68 0.56CKD 1282 (52%)49 (50%) 44 (44%)49 (50%) CKD 2150 (28%)27 (27%) 34 (34%)27 (27%) CKD 3104 (20%)23 (23%) 21 (22%)23 (23%) Oxford classification M score 0.93 0.50M0233 (45%)42 (44%) 39 (39%)42 (44%) M1288 (55%)53 (56%) 60 (61%)53 (56%) E score 0.55 0.71E0312 (60%)60 (63%) 60 (61%)60 (63%) E1209 (40%)35 (37%) 39 (39%)35 (37%) S score 0.33 0.14S0134 (26%)29 (31%) 21 (21%)29 (31%) S1387 (74%)66 (69%) 78 (79%)66 (69%) T score 0.35 0.02T0279 (54%)53 (56) % 43 (43%)53 (56%) T1181 (35%)27 (28%) 47 (48%)27 (28%) T261 (11%)15 (16%) 9 (9%)15 (16%) PSM: propensity score matching; HBV-: serum HBV negative; HBV+: serum HBV positive; SBP: systolic blood pressure; DBP: diastolic blood pressure; M: mesangial hypercellularity; E: endocapillary proliferation; S: segmental glomerulosclerosis; T: tubular atrophy/interstitial fibrosis. Baseline characteristics of patients with immunoglobulin a nephropathy stratified by HBV infection before and after propensity score matching. PSM: propensity score matching; HBV-: serum HBV negative; HBV+: serum HBV positive; SBP: systolic blood pressure; DBP: diastolic blood pressure; M: mesangial hypercellularity; E: endocapillary proliferation; S: segmental glomerulosclerosis; T: tubular atrophy/interstitial fibrosis. Primary outcome During a median follow-up time of 41 months (IQR: 24–62 months), the propensity-matched cohort observed 27 primary composite outcome events. Among these, seven (7%) occurred in the HBV-negative group, while 20 (20%) were observed in the HBV-positive group (Figure 2). The risk of HBV infection was 2.72 times higher risk of primary outcome events (adjusted hazard ratio, 2.22; 95% confidence interval, 0.89 to 5.53). Patients infected with HBV were also associated with higher risks of eGFR 30% decline and end-stage kidney disease, compared with those without HBV infection (Figure 3, Supplementary Table 1). In the subgroup analysis, the effects of HBV infection were consistent across subgroups stratified by age, sex, and eGFR. the detrimental associations of the HBV infection with primary outcomes were more prominent in patients with proteinuria less than 1.5 g/24h (Figure 4). The cumulative incidence of the primary composite outcome in the propensity-matched cohorts. The median follow-up was 41 months. The hazard ratio for the primary outcome in the HBV+ group compared to the HBV- group was 2.72 (95% CI: 1.15–6.48), with a p-value of 0.023. HBV+, patients with HBV infection; HBV-, patients without HBV infection. Comparison of renal outcomes between IgAN patients without HBV infection (HBV- group) and IgAN patients with HBV infection (HBV+ group). Forest plot illustrating the hazard ratios (HR) for renal outcomes. The boxes represent the HRs, and the horizontal lines indicate the 95% CI. The estimated effects of HBV infection on the primary composite outcome in subgroups. The impact of HBV antigens deposition in kidneys Among the 99 HBV+ patients, 23 patients missed HBsAg or HBcAg of immunofluorescence data in biopsy pathological information. Close to 20% (15/76) of IgA nephropathy patients infected with HBV had HBV-related antigens deposition in kidney tissues. The baseline characteristics and the latest follow-up characteristics of patients with and without HBV antigens deposition in kidney tissues are presented in Table 2 and Supplemental Table 2. Patients with HBV antigen deposition in the kidneys presented with lower baseline proteinuria levels, averaging 0.59 g/24h and exhibited optimal blood pressure and urine protein creatinine ratio at the most recent follow-up. The risk of HBV antigens deposition in the kidneys was associated with a 1.32 times higher risk of primary outcome events (Supplementary Table 3). Following adjustment for sex, age, albumin, blood pressure, urinary protein, and eGFR at the latest follow-up, the presence of HBV antigens deposition in kidneys was significantly associated with a 7.49-fold higher risk of primary outcome events (95% confidence interval, 1.00 to 56.04) (Figures 5, 6). Comparisons of Kaplan–Meier renal survival curves between IgAN without HBV deposition in kidneys (A) and those with HBV deposition in kidneys (B). Comparison of renal outcomes between IgAN patients without HBV antigens deposition (without HBV deposition) and IgAN patients with HBV antigens deposition in kidneys (with HBV deposition). Forest plot illustrating the hazard ratios (HR) for renal outcomes. The boxes represent the HRs, and the horizontal lines indicate the 95% CI. Table 2.The baseline characteristics of IgAN patients infected with HBV stratified by HBV antigen deposition in kidneys.VariablesBaseline characteristicsWithout HBV deposition in kidneys (n = 61)With HBV depositionin kidneys (n = 15)P valueAge, years34.56 (8.99)35.40 (12.95)0.98Male34 (55.74%)8 (53.33%)0.87SBP, mmHg127.30 (21.25)129.90 (18.33)0.55DBP, mmHg78.77 (12.67)77.93 (11.44)0.95Proteinuria, g/24h1.48 (1.38)0.59 (0.58)0.01Urine protein creatinine ratio677.9 (360, 1265)345.7 (210, 887.6)0.16eGFR, ml/min/1.73 m287.93 (28.34)94.85 (28.03)0.35Serum albumin, g/l39.13 (7.76)41.46 (9.86)0.36Oxford classification M score 0.97M026 (43%)6 (43%) M134 (57%)8 (57%) E score 0.15E042 (70%)7 (50%) E118 (30%)7 (50%) S score 0.23S016 (27%)6 (43%) S144 (73%)8 (57%) T score 0.57T032 (53%)9 (64%) T117 (28%)4 (29%) T211 (19%)1 (7%) SBP: systolic blood pressure; DBP: diastolic blood pressure; M: mesangial hypercellularity; E: endocapillary proliferation; S: segmental glomerulosclerosis; T: tubular atrophy/interstitial fibrosis; -: not involve. The baseline characteristics of IgAN patients infected with HBV stratified by HBV antigen deposition in kidneys. SBP: systolic blood pressure; DBP: diastolic blood pressure; M: mesangial hypercellularity; E: endocapillary proliferation; S: segmental glomerulosclerosis; T: tubular atrophy/interstitial fibrosis; -: not involve. Impact of medication on HBV antigens deposition in repeat kidney biopsies The medication utilization analysis is depicted in Table 3. There were no significant differences between the two groups regarding the use of RAAS inhibitors, nucleos(t)ide analogs, antihypertensive medications, steroids, or immunosuppressants. Among the 76 patients, three individuals underwent repeat renal biopsy. The medication usage and the expression of HBV DNA and antigens for the three patients are detailed in Figure 7. For case 1, the levels of HBV DNA, HBeAg, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were within the normal range. Despite treatment with entecavir, the HBsAg level remained significantly elevated, indicating the patient was HBeAg-negative chronic infection [20]. About two years later, renal deposition occurred in the patient’s kidneys. For case 2, the levels of HBV-DNA, HBsAg, and HBeAg were all elevated. After treatment with lamivudine, the HBV-DNA levels gradually decreased but remained higher than the normal range, ALT and AST were within the normal range indicating the patient was in an HBeAg-positive chronic infection. One year later, there were no antigen depositions observed in the patient’s kidneys. For case 3, the patient had an active HBV infection with HBV-DNA at 757,700 copies/ml, HBsAg over 300 ng/ml, and HBeAg above 75 PEIU/ml on March 12, 2012. No nucleos(t)ide analogue treatment was administered. The renal biopsy showed negative HBsAg and HBcAg. Four years later, HBV DNA decreased to 500 IU/ml and remained normal for at least 1 year. By the latest biopsy, the HBsAg level was above 250 ng/ml, HBeAg level was undetectable, indicating an HBeAg-negative chronic infection status. Repeat renal biopsy on June 27, 2017, revealed positive results for both HBsAg and HBcAg. Based on the cases presented, both Case 1 and Case 3 had HBV-DNA and HBeAg levels within normal ranges, with positive HBsAg, and both developed hepatitis B deposition in the kidneys. This suggests that patients with positive HBsAg should be vigilant about kidney deposition. In contrast, Case 2 showed active HBV status but did not exhibit deposition within one year, indicating that the time required for HBV antigens deposition in the kidneys may exceed one year. Comparison of HBV deposition in repeat kidney biopsy among three patients under different medication treatments. Normal range: HBV-DNA, 0–500 IU/ml; HBV-DNA, 0-500 copies/ml; HBsAg, 0–0.5 ng/ml (immunoassay method); HBsAg, 0–1 S/CO (chemiluminescence method); HBeAg, 0–0.5 PEIU/ml (immunoassay method); HBeAg, 0–1 S/CO (chemiluminescence method). Table 3.Medication information for IgAN patients with or without HBV deposition in kidneys.VariablesWithout HBV deposition in kidneys (n = 61)With HBV depositionin kidneys(n = 15)P valueMedication RAAS inhibitor56 (92%)13 (87%)0.62ACEI22 (36%)3 (20%)0.36ARB53 (87%)13 (87%)0.99Aldosterone inhibitor7 (11%)4 (27%)0.21β-blockers9 (15%)3 (20%)0.69Calcium-channel blockers15 (25%)3 (20%)0.99Diuretics10 (16%)3 (20%)0.71Glucocorticoid36 (59%)6 (40%)0.25Immunosuppressant24 (39%)5 (33%)0.77Nucleos(t)ide analogue41 (67%)9 (60%)0.76Hepatoprotective drug27 (44%)6 (40%)0.99Antiplatelet/anticoagulation40 (66%)4 (27%)0.01Lipid-lowering drugs15 (25%)4 (27%)0.99RAAS: renin-angiotensin-aldosterone system; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker. Medication information for IgAN patients with or without HBV deposition in kidneys. RAAS: renin-angiotensin-aldosterone system; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker. Discussion In our study, the infection rate of HBV in IgAN patients was 15.6%, which is higher than the infection rate in general population (7%). From this cohort study of a propensity-matched cohort of 198 patients with IgA nephropathy, our analysis indicated that HBV infection was correlated with a higher risk of kidney outcomes compared to HBV negative group which is consistent with previous study. HBV is not solely hepatotropic; it may directly infect renal tissues or impact the kidneys through mechanisms such as HBV-related cryoglobulinemia or immune-complex glomerulonephritis [21–24]. Our results showed that approximately 20% of IgAN patients infected with HBV have HBV antigens deposition in the kidneys. Compared to patients without deposition, those with deposition exhibited lower level of proteinuria at baseline. No differences were observed in other common clinical and pathological variables. With the use of medication, the latest follow-up characteristics indicated that patients with deposition not only manifest lower level of urine protein creatinine ratio but also demonstrate optimal blood pressure, which is not associated with RAAS inhibitors, β-blockers, calcium-channel blockers, glucocorticoid or immunosuppressant. Optimal blood pressure, compared with high-normal blood pressure in patients without deposition, is associated with a lower relative risk of developing end-stage kidney disease [25]. Lower urine protein levels are associated with better renal prognosis [26]. However, upon assessing the impact of renal antigens deposition on prognosis, interestingly, we observed that the risk for patients with deposition was 1.32 times higher compared to the no deposition group. After adjusting for the latest blood pressure and urinary protein results, as well as accounting for variables such as age, gender, and serum albumin levels, we discovered that the risk for patients with deposition was significantly elevated. The literature published this year demonstrated that HBV antigens deposition had no effect on renal outcomes [15]. The difference may be attributed to the use of anti-HBV medication. In our study, 66% of IgAN patients infected with HBV underwent antiviral treatment, whereas only 33% of patients received treatment in the study published this year. Current guidelines recommend antiviral treatment for HBV-DNA greater than 2000 IU/ml [27]. Our clinical experience indicated that HBV can complicate treatment. Therefore, antiviral therapy is proactive in our department. The data from three patients undergoing repeat renal biopsies suggested that for IgAN patients with HBeAg-negative or HBeAg-positive chronic infection, treatment strategies may benefit from achieving HBsAg clearance. However, given the small sample size, further studies are needed to validate these findings. Our study has several strengths. Initially, we utilized a propensity score to minimize confounding variables. Subsequently, we conducted comprehensive analysis of HBV antigens renal deposition status and meticulously assessed medication usage patterns. Furthermore, we also compared the deposition of HBV-related antigens in the kidneys of the same patients. Nonetheless, inherent limitations exist in our study. First, its observational design leaves potential for residual confounding. Second, the reliance on a database of Chinese patients needs cautious generalization of our findings to diverse ethnic populations. Conclusions HBV infection was associated with a higher risk of kidney outcomes in IgA nephropathy patients. Among IgAN patients with HBV infection, approximately 20% showed deposition of HBV antigens in the kidneys, which can impact renal prognosis. Achieving HBsAg clearance may help reduce the deposition of HBV antigens in renal tissue, potentially improving renal outcomes. However, due to the small sample size, further studies with larger cohorts are required to confirm these findings Supplementary Material Supplemental Material